Cargando…

Prognostic value and their clinical implication of 89-gene signature in glioma

Gliomas are the most common and aggressive primary tumors in adults. The current approaches, such as histological classification and molecular genetics, have limitation in prediction of individual therapeutic outcomes due to heterogeneity within the tumor groups. Recent studies have proposed several...

Descripción completa

Detalles Bibliográficos
Autores principales: Shahid, Muhammad, Cho, Kyoung Min, Nguyen, Minh Nam, Choi, Tae Gyu, Jo, Yong Hwa, Aryal, Saurav Nath, Yoo, Ji Youn, Yun, Hyeong Rok, Lee, Jae Woong, Eun, Young Gyu, Lee, Ju-Seog, Kang, Insug, Ha, Joohun, Yoon, Hwi-Joong, Kim, Si-Young, Kim, Sung Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239472/
https://www.ncbi.nlm.nih.gov/pubmed/27323413
http://dx.doi.org/10.18632/oncotarget.9983
Descripción
Sumario:Gliomas are the most common and aggressive primary tumors in adults. The current approaches, such as histological classification and molecular genetics, have limitation in prediction of individual therapeutic outcomes due to heterogeneity within the tumor groups. Recent studies have proposed several gene signatures to predict glioma's prognosis. However, most of the gene expression profiling studies have been performed on relatively small number of patients and combined probes from diverse microarray chips. Here, we identified prognostic 89 common genes from diverse microarray chips. The 89-gene signature classified patients into good and bad prognostic groups which differed in the overall survival significantly, reflecting the biological characteristics and heterogeneity. The robustness and accuracy of the gene signature as an independent prognostic factor was validated in three microarray and one RNA-seq data sets independently. By incorporating into histological classification and molecular marker, the 89-gene signature could further stratify patients with 1p/19q co-deletion and IDH1 mutation. Additionally, subset analyses suggested that the 89-gene signature could predict patients who would benefit from adjuvant chemotherapy. Conclusively, we propose that the 89-gene signature would have an independent and accurate prognostic value for clinical use. This study also offers opportunities for novel targeted treatment of individual patients.